Consequences of tumor planning target volume reduction in treatment of T2-T4 laryngeal cancer by unknown
Vugts et al. Radiation Oncology 2014, 9:195
http://www.ro-journal.com/content/9/1/195RESEARCH Open AccessConsequences of tumor planning target volume
reduction in treatment of T2-T4 laryngeal cancer
Cornelia AJM Vugts1, Chris HJ Terhaard2, Marielle EP Philippens2, Frank A Pameijer2, Nicolien Kasperts2
and Cornelis PJ Raaijmakers2*Abstract
Background and purpose: Since lymph nodes volumes are generally four times the volume of the primary PTV,
the advantage of using tight margins around the primary PTV is not clear. Therefore treatment margins of T2-T4
laryngeal carcinoma for IMRT are generally chosen in such a way that the PTV is comparable to that in conventional
radiotherapy. The aim of this study is to quantify the effect of volume reduction of the primary PTV of T2-T4 laryngeal
carcinoma with regard to late toxicity despite elective irradiation of lymph node levels II to IV.
Methods: Two treatment plans based on conservative (GTV-PTV = 15 mm and 20 mm cranial), and on
evidence-based tight margins (GTV-PTV = 8 mm) were calculated for 16 patients. Toxicity effects were estimated
based on the dose distributions.
Results: Compared to conservative margins, using tight margins resulted in: 1) significant reduction of the normal
tissue complication probability (NTCP) for swallowing muscles and submandibular glands, 2) significant reduction of
the mean dose in all organs at risk (OAR), 3) a mean dose smaller than 60 Gy for all OARs except for the laryngeal
cartilages. When the lymph node levels II to IV were prescribed with an elective dose, an NTCP reduction of 53% for
the swallowing muscles and of 23% for the submandibular glands was found by using tight instead of conservative
margins. When positive nodes were present, NTCP reduction amounted to 29% and 15%, respectively.
Conclusions: There is a potential benefit in realizing evidence-based tight margins for laryngeal cancer patients despite
elective irradiation of lymph node levels II to IV.
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The tumor control rate for advanced laryngeal carcinomas
is significantly improved using accelerated radiotherapy.
However, treatment intensification can be accompanied
by severe late toxicity [1-3]. Generally, less toxicity is
expected using reduced treated volumes [4-6].
Planning target volumes (PTV) can be reduced using
intensity modulated techniques. These techniques require
delineation of the gross target volume (GTV) and an
expansion of this volume according to ICRU 62 [7].
Today, treatment margins of laryngeal carcinomas when
applying intensity modulated techniques are generally
chosen in such a way that the PTV is comparable to* Correspondence: C.P.J.Raaijmakers@umcutrecht.nl
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reproduction in any medium, provided the orthat in conventional radiotherapy. This means that the
complete cartilage skeleton of the larynx is defined as
target volume [8-10]. Clear guidelines for margins to
define the clinical target volume (CTV) and the PTV are
not available yet [11]. Perez stated: ‘delineating the CTV is
more an art than a science because current imaging
techniques are not capable of detecting subclinical tumor
involvement directly’ [12].
Although tumor PTV reduction will apparently result in
decreased toxicity, this is not obvious in case of laryngeal
cancer including elective irradiation of lymph node levels
II to IV. The volume of the lymph nodes is generally four
times the volume of the adjacent PTV. The aim of this
study was to quantify the effect of volume reduction of
the primary PTV of T2-T4 laryngeal carcinoma with
regard to late toxicity despite elective irradiation of lymph
node levels II to IV. The effect on late toxicity is analysedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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probability (NTCP) of organs at risk (OARs) from treat-
ment plans based on tight and conservative margins.
Methods
Patients
The research was carried out in compliance with the
Helsinki declarations. Sixteen patients with T2–T4
supraglottic laryngeal carcinomas were included in
this planning study (Table 1). They were divided in
two subgroups based on TNM-stage. Group 1 included
patients prescribed with an elective dose to the volume
containing lymph node levels II to IV next to a high dose
to the primairy tumor (n = 10). Group 2 included patients
prescribed with a high dose to the primairy tumor and to
the positive lymph nodes and with an elective dose to the
whole volume of lymph node levels II to IV (n = 6).
Delineations
Target structures and OARs were delineated on the plan-
ning CT scan with a slice thickness of 2 mm. Delineations
were performed manually using in-house developed soft-
ware. In order to account for interobserver variation, the
primary tumor was delineated independently by two expe-
rienced head-neck radiation oncologists and one radiolo-
gist. The GTV was defined by union of these delineations.
Lymph node levels II to IV were delineated according to
the guidelines of Levendag et al. [13]. Delineated OARsTable 1 Patient characteristics
Patient TNM-stage GTV [cm3] PTVclinical [cm
3] PTVtight [cm
3]
Group 1 Patients without positive nodes
T3N0M0 6.6 92.6 49.3
T3N0M0 10.2 126.5 44.7
T2N0 8.1 105.1 51.9
cT2N0 3.1 76.5 34.4
cT2N0M0 7.1 78 39.8
cT3N0M0 2.3 47.9 21.4
T2N0 4.4 38.2 26.7
T4aN0M0 26.2 145.9 92.8
T3N0 6.9 82.5 44.4
T3N0M0 14.8 122.9 66.5
Group 2 Patients with positive nodes
T4N2c 20 96.7 83.6
T2N2cM1 9.3 30.8 20.7
T3n2cM0 20.6 166.4 98.7
T2N2xM1 9.1 100.8 52.9
T2N1 8.7 98.1 44.1
cT2N2bM0 9 110.7 57.6
Average 10.4 95.0 51.8included swallowing muscles, base of tongue, mucosa,
submandibular glands, arytenoids, cricoid - and thyroid
cartilage and carotid arteries. For delineation of the OARs,
a registered MRI scan in mask (gadolinium contrast en-
hanced T1 weighted, fat-suppressed, MRI) was used. The
SM were delineated as one structure extending from the
oropharynx to the inlet of the esophagus. All tissue ex-
tending less than 2 mm from the trachea, situated be-
tween the uvula and the C6 vertebra, was defined as
being mucosa (auto threshold grey value of −300 HU).
The carotid arteries were contoured from the uvula to
the lung apex. Care was taken to ensure that the differ-
ent target volumes did not extend within 4 mm of the
skin, to avoid PTV extension within the build-up region,
unless the tumor extended less than 5 mm underneath
the skin (Figure 1). CTV, internal target volume (ITV)
and PTV were obtained by the expansion of the GTV
using: 1) clinically applied, conservative margins and 2)
evidence based tight margins [1,7]. Anatomical margins
were corrected for anatomical boundaries and air.
Margins and dose prescription
The PTV of the nodal volumes resulted from a 5 mm
margin around the delineated volume and were prescribed
with a dose of 47 Gy (EQD2Gy = 45.9 Gy, α/β = 3 Gy). The
primary target volumes were prescribed with a dose of
69.5 Gy (EQD2Gy = 66.2 Gy, α/β = 3 Gy).
Clinically, the GTV was extended with a CTV-margin
of 15 mm and another 5 mm in cranial direction to
correct for swallowing induced tumor motion [14,15].
The CTV was extended with a uniform PTV-margin of
5 mm to result in the PTV (PTVclinical).
The PTV, resulting from using tight margins (PTVtight)
is defined by a uniform CTV-margin of 5 mm around
the GTV and an uniform PTV-margin of 3 mm around
the CTV (Figure 2). These tight margins can be used
without comprising the treatment of the GTV since:
– Recent studies indicate an over estimation of the
GTV delineated on the planning CT scan of more
than 3.5 mm [16,17].
– Preliminary results of a study in which GTV
delineations are validated with pathology showed
that there is in 10 out of 15 patients no
microscopical spread beyond 5 mm of the GTV
delineated on a CT scan [18].
– The incidence and total duration of swallowing is
low. Using adaptive radiotherapy with respect to
intrafraction tumor motion, internal margins can
even be omitted [14].
– Mean maximal GTV displacements (not swallowing
induced) are smaller than 3 mm [15].
– Improved stabilization materials in combination
with CBCT for daily image guidance can result in
Figure 2 Margin definition.
Figure 1 Target volumes and OARs on a transverse (upper) and
a coronal (lower) slice of a laryngeal cancer patient.
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errors smaller than 1 mm have been reported for
vocal cord irradiation [19,20].Fractionation
The dose fractionation was planned according to our
clinically used accelerated concomitant boost protocol
[1]. The first two weeks, five fractions of 2 Gy and in thelast three weeks, ten fractions of 1.5 Gy in the morning
and 1.8 Gy in the afternoon were prescribed. The time
between two fractions is at least 6 hours.
Treatment planning
For each patient, one intensity modulated radiotherapy
(IMRT) plan based on conservative margins and one based
on tight margins was generated. Treatment plans were cre-
ated with Monaco 3.0 (Elekta/CMS, Sweden, Stockholm).
The total dose distribution resulted from the addition of
two plans: a plan for the volumes with a prescribed dose of
47 Gy and a supplementary plan of 22.5 Gy for the vol-
umes with a prescribed dose of 69.5 Gy. The same tem-
plate with seven beam angles was applied in all plans.
NTCP calculation
The effect of the margin reduction on the dose to the
swallowing muscles and the submandibular glands was
qualified by calculating the NTCP. A dose response model
of Jackson et al. based on 428 patients was used to deter-
mine the NTCP for grade 2 swallowing dysfunction. This
model is based on the total volume of the swallowing
muscles (α = 1.6 Gy−1, γ50 = 2.6, EUD50 = 80.2 Gy) [21].
For the submandibular glands, a NTCP curve of Dijkema
et al. was used (TD50 = 35.0 Gy, m = 0.44). A complication
was defined as a flow of less than 25% of the pre-treatment
flow [22].
Statistics
Wilcoxon rank test for related samples was applied for
comparison of median values using an alpha level of
0.05 (SPSS inc., Chicago, USA).
Results
Target volume
Volume analysis yielded a mean GTV of 10.4 cm3.
PTVclinical had a mean volume of 95.0 cm
3 and PTVtight
of 51.8 cm3 (Table 1).
Figure 3 Sagittal view of a typical dose distribution, schematic (upper) and calculated (lower), resulting of using clinical (left) and tight
margins (right).
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In general, dose distributions were obtained that met
our criteria: 95% of the PTV was at least covered with
95% of the prescribed dose. The spinal cord was spared
in all plans with a maximum dose of 40 Gy. The volume
that received over 105% of the prescribed dose was
smaller than 3 cm3 (Figure 3).
The relative difference in dose between clinical and tight
margins was compared. A reduction in mean dose and
NTCP-value was found for all patients independently of
TNM-stage.
For patients without positive nodes, the NTCP decreased
by 53% for the swallowing muscles and by 23% for the
submandibular glands (Figure 4). When positive lymph
nodes were present, the NTCP decreased with respectively
29% and 15%.
The reduction in mean dose over all OARs was 16% in
group 1 versus 11% in group 2 (Figure 5). The differences
between median dose values and between NTCP values
were all statistically significant.
All OARs, except of the thyroid and the arytenoids,
received a mean dose lower than 60 Gy using tight
margins (Figure 4). Using conservative margins, no
OARs in group 2 and only the base of the tongue and
the submandibular glands in group 1 received a mean
dose lower than 60 Gy. Largest mean dose reduction
was observed in the base of the tongue and the cricoid.Figure 4 NTCP-values for the swallowing muscles and the
submandibular glands for laryngeal cancer patients (1) Patients
without positive nodes, (2) Patients with positive nodes. NTCP
values for tight margins (black boxes) were statistically significantly
lower than those for clinical margins (grey boxes).Discussion
Using our clinical margins, the PTV for laryngeal tumors
was about 10 times as large as the GTV. The PTV might
be reduced with 50% when evidence based tight margins
are applied. This volume reduction was advantageous
for all delineated OARs independent of the presence of
(elective) nodal volumes.Elective treatment of the lymph node levels II to IV
results in a large volume receiving a high radiation dose
[6,13]. Improved knowledge on recurrence patterns or
detailed lymph node imaging studies might facilitate
more specific delineation of nodal regions which will
Figure 5 Mean dose reduction. Mean dose values for tight
margins (black boxes) were statistically significantly lower than those
for clinical margins (grey boxes).
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carcinoma.
The relative importance of the various anatomical
structures and substructures in causing radiation toxicity
is the subject of current research [3,4,23]. Therefore,
various OARs were analysed in this study. Toxicity was
estimated in two ways: mean dose and NTCP. The con-
straint of mean dose lower than 60 Gy was analyzed
since it has been shown that a dose limitation of 60 Gy
to the larynx results in a low risk of aspiration [9].
The NTCP is the best estimate of complication risk.
However dose response models of most OARs in the
head-and-neck region are currently not available since
OARs in this region were historically homogeneously
irradiated.
Several studies have been performed that show a
dose-volume-effect of the swallowing muscles for
dysphagia. However, a clinically relevant dose response
model obtained in a large patient population is lacking
[23,24]. Levendag et al. proposed a subdivision of the
swallowing muscles in five structures and published a
dose response curve for the cranial part of the swallowing
muscles [25]. The use of this model will result in a larger
gain in NTCP than using the model of Jackson based
on the total volume of the swallowing muscles [21]. We
decided to define the swallowing muscles as one structure,
since the exact contribution of the different structures
to radiation induced complication has not been fully
understood.
The largest reduction in mean dose was observed in
the base of the tongue and the cricoid. These structures
are most of the time located outside of the target volume
when tight margins are used.When elective lymph node regions are included, a
simultaneous integrated boost (SIB) technique may give
better organ sparing than a separate consecutive boost
due to beneficial dose distribution. However a SIB treat-
ment will lead to increased toxicity due to high fraction
doses in normal tissue within the high dose region.
In this work we translated new insight and techniques
applied for laryngeal cancer irradiation to optimized treat-
ment margins and quantified the clinical benefits. At our
department this work has resulted in a reduction of the
CTV-PTV margin to 3 mm and a reduction of the margin
applied for internal motion. For a reduction of the GTV-
CTV margin more results from the pathology studies are
awaited.
Although definitive guidelines for laryngeal tumor delin-
eation and margins cannot be given, the results from this
study indicate that further research in this area is needed
and might result in significantly reduced toxicity.
Conclusion
Applying tight margins around the primary tumor in
laryngeal carcinoma theoretically resulted in 45% less
late toxicity for the swallowing muscles and 20% for the
submandibular glands compared to conservative margins,
independent of treatment of the lymph node levels II
to IV. Therefore it is worth to translate the results
from image validation, microscopic extension and tumor
motion studies into guidelines for evidence based tight
margins around the primary tumor of supraglottic laryn-
geal cancer patients which can be implemented in clinical
practice.
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